shire
Shire, Baxalta to announce merger as soon as Monday: sources
January 7, 2016 by elegant · Leave a Comment
The deal would come after Reuters first reported on Dec. 22 that Shire's latest offer for Baxalta had met the latter's valuation expectations. Baxalta shares were trading on Thursday just under $39 and Shire stock was at $190.45 a share. Both parties are confident tax concerns arising from Baxalta's spin out from Baxter International Inc will not be an impediment to the transaction but are waiting for a formal legal opinion to come through before signing their merger agreement, the people added.
The rest is here:
Shire, Baxalta to announce merger as soon as Monday: sources
shire
Record highs predicted for bitcoin in 2016 as new supply halves
December 23, 2015 by admin · Leave a Comment
The reason 2016 looks set to be different is that bitcoin's price is likely to be driven in large part by similar factors to a traditional fiat currency, following the age-old principles of supply and demand. Instead of being controlled by a central bank, bitcoin relies on so-called “mining” computers that validate blocks of transactions by competing to solve mathematical
More here:
Record highs predicted for bitcoin in 2016 as new supply halves
shire
Exclusive: Shire closer to deal to buy Baxalta – sources
December 23, 2015 by creative · Leave a Comment
By Carl O'Donnell and Pamela Barbaglia NEW YORK/LONDON (Reuters) – Drug maker Shire Plc has made a new acquisition offer for peer Baxalta International Inc that is roughly in line with the latter's valuation expectations, making a deal…
View post:
Exclusive: Shire closer to deal to buy Baxalta – sources
shire
Shire to buy Dyax for $5.9 billion, still wants Baxalta
November 2, 2015 by elegant · Leave a Comment
Shire Plc has agreed to buy U.S. rare disease specialist Dyax Corp for about $5.9 billion – and potentially up to $6.5 billion – while still pursuing a five times larger unsolicited bid for Baxalta Inc . Given its existing HAE presence, Ornskov acknowledged the deal would be scrutinized by antitrust authorities and he said Shire was already preparing for this.
Here is the original:
Shire to buy Dyax for $5.9 billion, still wants Baxalta